Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2014 Sep 26;2014(9):CD007595.
doi: 10.1002/14651858.CD007595.pub3.

Repeated use of pre- and postcoital hormonal contraception for prevention of pregnancy

Vera Halpern  1 , Elizabeth G Raymond, Laureen M Lopez
Affiliations
Meta-Analysis

Repeated use of pre- and postcoital hormonal contraception for prevention of pregnancy

Vera Halpern et al. Cochrane Database Syst Rev. .

Abstract

Background: Repeated use of postcoital hormonal contraception is not currently recommended due to the higher risk of side effects and lower contraceptive effectiveness compared to other modern methods of contraception. However, emerging evidence indicates renewed interest in a regular coitally-dependent method of oral contraception. We evaluated the existing data on safety and effectiveness of pericoital use of levonorgestrel and other hormonal drugs to prevent pregnancy.

Objectives: To determine the effectiveness and safety of repeated use of pre- and postcoital hormonal contraception for pregnancy prevention.

Search methods: We searched until 1 September 2014 for trials that tested repeated pre- and postcoital use of hormonal drugs for pregnancy prevention. Databases included CENTRAL, MEDLINE, and POPLINE. We searched for current trials via ClinicalTrials.gov and ICTRP. For the initial review, we also searched EMBASE, CINAHL, and LILACS, and wrote to researchers to identify other trials.

Selection criteria: We considered published and unpublished studies of repeated postcoital or immediately precoital use of hormonal drugs for contraception with pregnancy as an outcome.

Data collection and analysis: Two authors independently confirmed eligibility and extracted data from the included studies. We calculated confidence intervals (CI) around individual study Pearl indices using a Poisson distribution. We presented individual study estimates and pooled estimates and their 95% CI, where appropriate.

Main results: We found 22 trials that evaluated pericoital use of LNG and other hormonal drugs on a regular basis to prevent pregnancy. The studies included a total of 12,400 participants, and were conducted in Europe, Asia, and the Americas. The drugs and doses evaluated included levonorgestrel (LNG) 0.75 mg (11 studies), LNG in doses other than 0.75 mg (4 trials), and hormones other than LNG (7 trials). Outcomes included pregnancy rates, discontinuation, side effects, and acceptability.Pericoital levonorgestrel was reasonably efficacious and safe. The pooled Pearl Index for the 0.75 mg dose of LNG was 5.4 per 100 woman-years (95% CI 4.1 to 7.0). The pooled Pearl Index for all doses of LNG was 5.0 per 100 woman-years (95% CI 4.4 to 5.6). Other hormonal drugs appeared promising but most of them were not studied extensively. Menstrual irregularities were the most common side effects reported. However, the studies provided no consistent evidence of a relationship between bleeding abnormalities and either frequency of pill intake or total dose of the drug. Non-menstrual side effects were reportedly mild and not tabulated in most studies. Most women liked the pericoital method in spite of frequent menstrual irregularities.

Authors' conclusions: The studies of pericoital LNG regimens provided promising results but many had serious methodological issues. Most reports were decades old and provided limited information. However, we considered the evidence to be moderate quality because of the large number of participants from diverse populations, the low pregnancy rates, and the consistent results across studies. Rigorous research is still needed to confirm the efficacy and safety of pericoital use of LNG as a primary means of contraception among women with infrequent intercourse. If the method is shown to be efficacious, safe and acceptable, the results may warrant revision of the current World Health Organization recommendations and marketing strategies.

PubMed Disclaimer

Conflict of interest statement

Taylor 2014 was conducted by FHI 360, where V Halpern and L Lopez are employed; E Raymond had worked there during the study planning. V Halpern and E Raymond were investigators in that study. D Taylor from FHI 360 was an investigator on that study and calculated the pooled Pearl index for the LNG 0.75 mg studies in 2014.

Update of

References

References to studies included in this review

Canzler 1984 {published data only}
    1. Canzler VE, Ahrendt HJ, Ahrendt S. Experience with LNG for postcoital contraception. Zentralblatt für Gynäkologie 1984;106:1182‐91. - PubMed
Chernev 1995 {published data only}
    1. Chernev T, Ivanov S, Dikov I, Stemenkova R. Prospective study of contraception with LNG. Planned Parenthood in Europe 1995;24(2):25. - PubMed
Cox 1968 {published data only}
    1. Cox HJE. The pre‐coital use of mini‐dosage progestagens. Journal Reproduction and Fertility 1968;Suppl 5:167‐72.
Echeverry 1974 {unpublished data only}
    1. Echeverry G, Sarria C. High doses of d‐norgestrel as a postcoital contraception. Report on file 1974.
He 1991 {published data only}
    1. He CH, Shi YE, Xu JQ, Look PFA. A multicenter clinical study on two types of LNG tablets administered for postcoital contraception. International Journal of Gynecology and Obstetrics 1991;36:43‐8. - PubMed
Kesseru 1973 {published data only}
    1. Kesseru E, Larranga A, Parada J. Postcoital contraception with d‐Norgestrel. Contraception 1973;7:367‐79.
Klawe 1984 {published data only}
    1. Klawe H, Iwaszkiewicz J. Preliminary results of investigations of Postinor. Report on file 1984; Vol. 26:29.
Kliment 1986 {published data only}
    1. Kliment V, Ziak F, Stanislav D, Hronec M. Postcoital contraception. Ceskoslovenska Gynekologie 1986;51:103‐5. - PubMed
Larranga 1975 {published data only}
    1. Larranga A, Winterhaltel M, Sartoretto JN. Evaluation of d‐Norgestrel 1.0 mg as a post‐coital contraceptive. International Journal of Fertility 1975;20:156‐60. - PubMed
Mischler 1974 {published data only}
    1. Mischler TW, Rubio B, Larranga A, Guiloff E, Moggia A. Further experience with quingestanol acetate as a postcoital oral contraceptive. Contraception 1974;9:221‐5. - PubMed
Moggia 1974 {published data only}
    1. Moggia A, Beauquis A, Ferrari F, Torrado M, Alonso J, Koremblit E, et al. The use of progestogens as postcoital oral contraceptives. Journal of Reproductive Medicine 1974;13:58‐61. - PubMed
Nirapathpongporn {unpublished data only}
    1. Nirapathpongporn A, Antarikanonda P. Postcoital contraception with 0.75 mg LNG (Postinor) in Thai women. Report on file (data collected 1984 to 1985).
Rubio 1970 {published data only}
    1. Rubio B, Berman E, Larranga A, Guiloff E. A new postcoital oral contraceptive. Contraception 1970;1:303‐13.
Sas {unpublished data only}
    1. Sas M, Farkas M, Apro G. On the oral postcoital contraceptive Postinor containing 0.75mg of d‐norgestrel per tablet. Report on file (undated).
Schering 1978 {unpublished data only}
    1. Schering AG. Clinical results of SH 9.0999 P (post‐coital pill containing 600 µg LNG) in semi‐continuous use (as supplied 04 Nov 2008). Report on file 1978.
Seregely 1982 {published data only}
    1. Seregely G. Results of a multicenter trial of Postinor. Therapia Hungarica 1982;30:72‐8. - PubMed
Szontagh 1969 {published data only}
    1. Szontagh FE, Kovacs L. Post‐coital contraception with dienoestrol. Medical Gynaecology and Sociology 1969;4:36‐7. - PubMed
Taylor 2014 {published and unpublished data}
    1. Halpern V. Pericoital oral contraception with levonorgestrel. http://clinicaltrials.gov/show/NCT00922233 (accessed 5 February 2014). - PubMed
    1. Taylor DJ, Lendvay A, Halpern V, Bahamondes LG, Fine PM, Ginde SY, et al. A single‐arm study to evaluate the efficacy, safety and acceptability of pericoital oral contraception with levonorgestrel. Contraception 2014;89(3):215‐21. - PubMed
WHO 1987 {published data only}
    1. Bhattacharjee SK, Romeo J, Kononova ES, Pretnar‐Darovec A, Saraya L, Shi YE, et al. Postcoital contraception with LNG during the peri‐ovulatory phase of the menstrual cycle. Task Force on Post‐ovulatory Methods for Fertility Regulation. Contraception 1987;36:275‐86. - PubMed
WHO 2000 {published data only}
    1. United Nations Development Programme/United Nations Population Fund/World Health Organization/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Task Force on Post‐Ovulatory Methods of Fertility Regulation. Efficacy and side effects of immediate postcoital LNG used repeatedly for contraception. Contraception 2000;61:303‐8. - PubMed
Zanartu 1974 {published data only}
    1. Zanartu J, Dabancens A, Oberti C, Rodriquez‐Bravo R, Garcia‐Huidobro M. Low‐dosage oral progestogens to control fertility. Obstetrics and Gynecology 1974;43:87‐96. - PubMed
Zanartu 1976 {published data only}
    1. Zanartu J, Oberti C. An oral progestogen as a coital contraceptive: experimental clinical study. In: Moghissi KS, Evans TN editor(s). Regulation of Human Fertility. Detroit (MI): Wayne State University Press, 1976:101‐14.

References to studies excluded from this review

Czekanowski {unpublished data only}
    1. Czekanowski R, Adamski M. Effectiveness of contraceptive Postinor. Report on file (undated).
Hetenyi 1988 {published data only}
    1. Hetenyi G. Comparative study of anteovin, rigevidon and postinor in young people. Medicus Universalis Terapias Melleklet 1988;May:2‐4.
Hurtado 1975 {published data only (unpublished sought but not used)}
    1. Hurtado H, Kesseru E, Larranga A, Benavides G. Post‐coital contraception with d‐norgestrel: evaluation of nine doses. Reproduccion 1975;2:61.
Krymskaya 1983 {published data only}
    1. Krymskaya ML, Khomasuridze AG. Clinical aspects of the use of current oral contraceptives. Akusherstvo Gynecologiya 1983;11:19‐22. - PubMed
Kulakov 1983 {published data only}
    1. Kulakov VI, Barinov AM, Prilepskaya VN. Contraceptive use of ovidon, rigevidon and postinor. Akusherstvo Gynecologiya 1983;11:22‐4. - PubMed
Orley {unpublished data only}
    1. Orley J. Report on the clinical trial of Postinor. Report on file (undated).
Serov 1983 {published data only}
    1. Serov VN, Glebova VV, Shakhova AD. Clinical use of rigevidon, ovidon and postinor. Akusherstvo Gynecologiya 1983;11:17‐9. - PubMed
Szczurowicz {unpublished data only}
    1. Szczurowicz A, Witczak A. Clinical evaluation of Postinor. Report on file undated.
Unzeitig 1989 {published data only}
    1. Unzeitig V, Mullerova M, Buresova A, Soska J. Interception ‐ three years of experience. Ceskoslovenska Gynekologie 1989;54:192‐5. - PubMed
Vasilev 1983 {published data only}
    1. Vasilev D, Katsarova M. Our experience with clinical testing of Postinor ‐ a hormonal oral preparation for postcoital contraception [article in Bulgarian]. Akusherstvo i Ginekologiia 1983;22:239‐42. - PubMed

References to ongoing studies

WHO 2014 {published and unpublished data}
    1. World Health Organization. Pericoital oral contraception with levonorgestrel among reproductive aged‐women who have infrequent intercourse to investigate its safety and efficacy. https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=320673 (accessed 30 January 2014). [ACTRN12611001037998]

Additional references

ACOG 2010
    1. American College of Obstetricians and Gynecologists. Emergency contraception. Practice Bulletin 2010; Vol. 112:1100‐9.
Arowojolu 2000
    1. Arowojolu AO, Adekunle AO. Perception and practice of emergency contraception by post‐secondary school students in Southwest Nigeria. African Journal of Reproductive Health 2000;4:56‐65. - PubMed
Balshem 2011
    1. Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology 2011;64(4):401‐6. - PubMed
Britwum 2006
    1. Britwum PK. What one should know about the drug 'N' tablet. Ghana Pharmaceutical Journal 2006:67‐8.
Croxatto 2003
    1. Croxatto HB, Ortiz ME, Muller AL. Mechanism of action of emergency contraception. Steroids 2003;68:1095‐8. - PubMed
Farkas 1981
    1. Farkas M, Apro G, Sas M. Clinico‐pharmacological examination of Postinor. Therapia Hungarica 1981;29:22‐30. - PubMed
Foster 2013
    1. Foster DG, Biggs MA, Grossman D, Schwarz EB. Interest in a pericoital pill among women in family planning and abortion clinics. Contraception 2013;88(1):141‐6. - PubMed
Frost 2009
    1. Frost J (Guttmacher Institute). Data on women who have infrequent sex. Email to: EG Raymond 6 July 2009.
He 1990
    1. He C, Shi Y, Liao D, Zhu Y, Xu J, Matlir SA, et al. Comparative cross‐over pharmacokinetic study on two types of postcoital contraceptive tablets containing levonorgestrel. Contraception 1990;41:557‐67. - PubMed
Herbenick 2010
    1. Herbenick D, Reece M, Schick V, Sanders SA, Dodge B, Fortenberry JD. Sexual behaviors, relationships, and perceived health status among adult women in the United States: results from a national probability sample. Journal of Sexual Medicine 2010;7(Suppl 5):277‐80. - PubMed
Higgins 2011
    1. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane‐handbook.org.
Lerkiatbundit 2000
    1. Lerkiatbundit S, Reanmongkol W. Use of 0.75 mg levonorgestrel for postcoital contraception in Thailand. Journal of Clinical Pharmacy and Therapeutics 2000;25:185‐90. - PubMed
Lo 2012
    1. Lo SST, Ho P‐C. Changes in contraceptive choice after emergency contraception. International Journal of Gynecology and Obstetrics 2012;118(3):223‐6. - PubMed
Morris 1973
    1. Morris JM, Wagenen G. Interception: the use of postovulatory estrogens to prevent implantation. American Journal of Obstetrics and Gynecology 1973;115:101‐6. - PubMed
Novikova 2007
    1. Novikova N, Weisberg E, Stanczyk FZ, Croxatto HB, Fraser IS. Effectiveness of LNG emergency contraception given before or after ovulation ‐ a pilot study. Contraception 2007;75:112‐8. - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Seregely 1977
    1. Seregely G, Vero T. Postcoital contraception with 0.75 mg d‐Norgestrel (Postinor). Magyar Noorvosok Lapia 1977;40:31‐4. - PubMed
Taylor 2009
    1. Taylor D (FHI 360). Interpretation of pooled pregnancy rate. Email to: EG Raymond 29 June 2009.
Trussell 1991
    1. Trussell J. Methodological pitfalls in the analysis of contraceptive failure. Statistics in Medicine 1991;10:201‐10. - PubMed
Trussell 2011
    1. Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397‐404. - PMC - PubMed
Trussell 2014
    1. Trussell J, Raymond EG, Cleland K. Emergency contraception: a last chance to prevent unintended pregnancy. http://ec.princeton.edu/questions/ec‐review.pdf (accessed 4 February 2014).

Publication types

MeSH terms

Substances

LinkOut - more resources